Skip to main content

Table 4 Cost and cost-effectiveness of universal GA-I newborn screening at differing prevalence rates and low versus high incremental screening cost

From: Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis

 

Incremental screening cost 0.03 Euro/neonate

Incremental screening cost 0.3 Euro/neonate

Prevalence

Mean incremental cost per 100000 screened neonates (95% CI)

ICER

Mean incremental cost per 100000 screened neonates (95% CI)

ICER (95% CI)

1 in 35,000

−103,445 (−160,339 – -52,919)

<0

−76,545 (−133,439 – -26,019)

<0

1 in 100,000

−34,191 (−54,104 – -16,507)

<0

−7,291 (−27,204 – 10,393)

−1,750 (−6,417 - 2,657)

1 in 200,000

−15,545 (−25,502 – -6,703)

<0

11,355 (1,398 – 20,197)

5,703 (651 – 10,728)

1 in 350,000

−7,555 (− 13,244 – - 2,502)

<0

19,345 (13,656 – 24,398)

16,882 (10,800 – 23,491)

  1. All values in Euro, 20 years horizon.